Pepcid AC
This article was originally published in The Tan Sheet
Executive Summary
Launch of generic versions of market-leading OTC H2 antagonist apparently delayed due to patent dispute, FDA says. J&J/Merck's famotidine 10 mg had received six months of pediatric exclusivity, which expired April 15
You may also be interested in...
Perrigo New Product Launches, PPA Replacements Slated For August
Perrigo expects to offer famotidine Acid Reducer, a generic version of J&J/Merck's Pepcid AC, no later than June, the private labeler told analysts during a conference call May 1.
Perrigo New Product Launches, PPA Replacements Slated For August
Perrigo expects to offer famotidine Acid Reducer, a generic version of J&J/Merck's Pepcid AC, no later than June, the private labeler told analysts during a conference call May 1.
Perrigo New Product Launches, PPA Replacements Slated For August
Perrigo expects to offer famotidine Acid Reducer, a generic version of J&J/Merck's Pepcid AC, no later than June, the private labeler told analysts during a conference call May 1.